Find in Library
Search millions of books, articles, and more
Indexed Open Access Databases
T2/FLAIR Abnormity Could be the Sign of Glioblastoma Dissemination
oleh: Mingxiao Li, Mingxiao Li, Wei Huang, Wei Huang, Hongyan Chen, Haihui Jiang, Chuanwei Yang, Chuanwei Yang, Shaoping Shen, Shaoping Shen, Yong Cui, Yong Cui, Gehong Dong, Xiaohui Ren, Xiaohui Ren, Xiaohui Ren, Song Lin, Song Lin, Song Lin
Format: | Article |
---|---|
Diterbitkan: | Frontiers Media S.A. 2022-02-01 |
Deskripsi
PurposeNewly emerged or constantly enlarged contrast-enhancing (CE) lesions were the necessary signs for the diagnosis of glioblastoma (GBM) progression. This study aimed to investigate whether the T2-weighted-Fluid-Attenuated Inversion Recovery (T2/FLAIR) abnormal transformation could predict and assess progression for GBMs, especially for tumor dissemination.MethodsA consecutive cohort of 246 GBM patients with regular follow-up and sufficient radiological data was included in this study. The series of T2/FLAIR and T1CE images were retrospectively reviewed. The patients were separated into T2/FLAIR and T1CE discordant and accordant subgroups based on the initial progression images.ResultsA total of 170 qualified patients were finally analyzed. The incidence of discordant T2/FLAIR and T1CE images was 25.9% (44/170). The median time-span of T2/FLAIR indicated tumor progression was 119.5 days (ranging from 57 days-unreached) prior to T1CE. Nearly half of patients (20/44, 45.5%) in the discordant subgroup suffered from tumor dissemination, substantially higher than accordant patients (23/126, 20.6%, p < 0.001). The median time to progression (TTP), post-progression survival (PPS), and overall survival (OS) were not statistically different (all p > 0.05) between discordant and accordant patients.ConclusionsT2/FLAIR abnormity could be the sign of GBM progression, especially for newly emerged lesions disseminating from the primary cavity. Physicians should cast more attention on the dynamic change of T2/FLAIR images, which might be of great significance for progression assessment and subsequent clinical decision-making.